---
schema_version: "secwatch.filing_event.v1"
accession: "0001494650-24-000068"
form_type: "8-K"
ticker: null
cik: "0001494650"
company_name: "OptiNose, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:43:21.542260+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Optinose Q1 XHANCE revenue $14.9M (+26% YoY); FDA approval for chronic sinusitis; guides FY24 rev $85-95M

## Summary
- Q1 net revenue $14.9M (+26% YoY); net loss $14.1M ($0.12/shr) vs $18.8M ($0.17) prior year.
- FDA approved XHANCE for chronic rhinosinusitis without nasal polyps on Mar 15, 2024 (first Rx treatment).
- FY24 guidance: XHANCE net rev $85-95M; avg rev per Rx >$230 (prev ~$220); GAAP op ex $95-101M.
- Expects positive GAAP income from operations for full year 2025.
- Completed $55M registered direct offering May 10; pro forma cash ~$100M sufficient through 2025.

## SEC filing metadata
- accession: 0001494650-24-000068
- form_type: 8-K
- cik: 0001494650
- company_name: OptiNose, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1494650/000149465024000068/0001494650-24-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1494650/000149465024000068/optn-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001494650-24-000068
- JSON: https://secwatch.observer/filing/0001494650-24-000068.json
- Plain text: https://secwatch.observer/filing/0001494650-24-000068.txt

## Key facts
- Earnings Releases
  OptiNose, Inc. reported quarter ended March 31, 2024 results: revenue $14.9 million, net income $14.1 million, EPS $0.12 per share. Guidance raised.
  - Period: quarter ended March 31, 2024
  - Revenue: $14.9 million
  - Net income: $14.1 million
  - EPS: $0.12 per share
  - Guidance: raised
  - Result: reported results
  source text: First Quarter 2024 Financial Results Total revenues The Company reported $14.9 million in net revenue from sales of XHANCE during the three-month period ended March 31, 2024, an increase of 26% compared to $11.8 million during the three-month period ended March 31, 2023. Costs and expenses and net loss For the three-month period ended March 31, 2024, research and development expenses were $1.2 million and selling, general and administrative expenses were $20.5 million. The net loss for the period was $14.1 million, or $0.12 per share (basic and diluted).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1494650/000149465024000068/0001494650-24-000068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.